Xiao Ma1, Yang Chen2, Shawn H Reginauld2, Christopher G Scott3, Seethalakshmi R Iyer2, Jacob J Schaefer2, Tomoko Ichiki4, Horng H Chen2, Andrew D Rule5, John C Burnett6, S Jeson Sangaralingham7. 1. Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Ma.Xiao@mayo.edu. 2. Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA. 4. Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Department of Cardiology, International University of Health and Welfare, Narita, Japan. 5. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. 6. Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA. 7. Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Sangaralingham.Jeson@mayo.edu.
Abstract
OBJECTIVES: This study sought to characterize urinary and plasma C-type natriuretic peptide (CNP) in acute decompensated heart failure (ADHF) to define their relationship with clinical variables and to determine whether urinary and plasma CNP together add prognostic value. BACKGROUND: CNP is a protective hormone that is synthesized in the kidney and endothelium and possesses antiremodeling properties. Urinary and plasma CNP levels are elevated in pathophysiological conditions; however, their regulation and prognostic value in heart failure (HF) is unclear. METHODS: Urinary and plasma CNP were measured in 109 healthy subjects and 208 patients with ADHF; the 95th percentile of CNP values from healthy subjects established the normal contemporary cutoffs. Patients with ADHF were stratified based on urinary and plasma CNP levels for clinical characterization and the assessment of risk for adverse outcomes. RESULTS: There was no significant correlation between urinary and plasma CNP in both cohorts. Urinary and plasma CNP were significantly elevated in patients with ADHF, and both increased with disease severity and were positively correlated with plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP). Of the patients with ADHF, 23% had elevations in both urinary and plasma CNP, whereas 24% had normal CNP levels. During a median follow-up of 3 years, patients with elevated urinary and plasma CNP had a significantly higher risk of rehospitalization and/or death (HR: 1.79; P = 0.03) and rehospitalization (HR: 2.16; P = 0.01) after adjusting for age, sex, left ventricular ejection fraction, renal function, and plasma NT-proBNP. The C-statistic and integrated discrimination analyses further supported that the addition of urinary and plasma CNP to established risk models improved the prediction of adverse outcomes in patients with ADHF. CONCLUSIONS: Urinary and plasma CNP are differentially regulated in ADHF, and elevations in both provided independent prognostic value for predicting adverse outcomes.
OBJECTIVES: This study sought to characterize urinary and plasma C-type natriuretic peptide (CNP) in acute decompensated heart failure (ADHF) to define their relationship with clinical variables and to determine whether urinary and plasma CNP together add prognostic value. BACKGROUND: CNP is a protective hormone that is synthesized in the kidney and endothelium and possesses antiremodeling properties. Urinary and plasma CNP levels are elevated in pathophysiological conditions; however, their regulation and prognostic value in heart failure (HF) is unclear. METHODS: Urinary and plasma CNP were measured in 109 healthy subjects and 208 patients with ADHF; the 95th percentile of CNP values from healthy subjects established the normal contemporary cutoffs. Patients with ADHF were stratified based on urinary and plasma CNP levels for clinical characterization and the assessment of risk for adverse outcomes. RESULTS: There was no significant correlation between urinary and plasma CNP in both cohorts. Urinary and plasma CNP were significantly elevated in patients with ADHF, and both increased with disease severity and were positively correlated with plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP). Of the patients with ADHF, 23% had elevations in both urinary and plasma CNP, whereas 24% had normal CNP levels. During a median follow-up of 3 years, patients with elevated urinary and plasma CNP had a significantly higher risk of rehospitalization and/or death (HR: 1.79; P = 0.03) and rehospitalization (HR: 2.16; P = 0.01) after adjusting for age, sex, left ventricular ejection fraction, renal function, and plasma NT-proBNP. The C-statistic and integrated discrimination analyses further supported that the addition of urinary and plasma CNP to established risk models improved the prediction of adverse outcomes in patients with ADHF. CONCLUSIONS: Urinary and plasma CNP are differentially regulated in ADHF, and elevations in both provided independent prognostic value for predicting adverse outcomes.
Authors: Yang Chen; Gail J Harty; Ye Zheng; Seethalakshmi R Iyer; Shinobu Sugihara; S Jeson Sangaralingham; Tomoko Ichiki; Joseph P Grande; Hon-Chi Lee; Xiaoli Wang; John C Burnett Journal: Circ Res Date: 2019-05-10 Impact factor: 17.367
Authors: Mathias Knecht; Ines Pagel; Thomas Langenickel; Sebastian Philipp; Michaela Scheuermann-Freestone; Thomas Willnow; Dennis Bruemmer; Kristof Graf; Rainer Dietz; Roland Willenbrock Journal: Life Sci Date: 2002-10-25 Impact factor: 5.037
Authors: Pamela N Peterson; John S Rumsfeld; Li Liang; Nancy M Albert; Adrian F Hernandez; Eric D Peterson; Gregg C Fonarow; Frederick A Masoudi Journal: Circ Cardiovasc Qual Outcomes Date: 2009-12-08
Authors: Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader Journal: Proc Natl Acad Sci U S A Date: 2006-03-14 Impact factor: 11.205
Authors: Suetonia C Palmer; Timothy C R Prickett; Eric A Espiner; Timothy G Yandle; A Mark Richards Journal: Hypertension Date: 2009-07-20 Impact factor: 10.190
Authors: Kevin Damman; Mattia A E Valente; Adriaan A Voors; Christopher M O'Connor; Dirk J van Veldhuisen; Hans L Hillege Journal: Eur Heart J Date: 2013-10-27 Impact factor: 29.983